Eli Lilly has announced the launch of additional higher-dose vials of its weight-loss drug Zepbound, offering these in more competitive price points, including a reduction of $150 compared to injector pens. The company is focused on making the drug more accessible for self-pay patients and is introducing significant savings under its Self Pay Journey Program. This move comes as a strategic response to the increasing competition in the weight-loss medication market, aiming to combat cheaper alternatives and enhance patient options. Additionally, Lilly has unveiled several new doses in their vial offerings while lowering prices for existing products to further expand access and affordability for consumers.